At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
Enoxaparindrug
Likely dose
Enoxaparin 0.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Randomized Controlled Trial of Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
In Brief
A Phase 2 clinical trial evaluating Enoxaparin for Thromboembolism. Completed, enrolled 64 participants across 1 site.
Detailed Summary
The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery. The investigators hypothesize that among eligible individuals, at least 35% will enroll, undergo randomization, and complete the allocated treatment group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThromboembolism
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartOct 2023
First PostedNov 2023
Primary CompletionJul 2024
TodayJul 2026
First PostedNov 7, 2023
Enrollment StartOct 11, 2023
Primary CompletionJul 1, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 2.7 years ago
Interventions
Enoxaparindrug
Participants will receive weight-based dosing of enoxaparin at 0.5 mg/kg rounded to the nearest 10 mg every 12 hours based on delivery admission weight. Participants will receive therapy for 14 days.